On October 13, 2021, the Buck Institute for Research on Aging and the Astera Institute announced a $70 million collaboration through which they will launch the Rejuvenome Project, a first-of-its-kind comprehensive, multi-omics study of the biological effects of longevity interventions. Through a series of large-scale lifespan studies in genetically diverse mice, researchers will test interventions, both alone and in combination, known or suspected to impede or reverse aging and extend longevity. The work aims to create an open and comprehensive dataset to better understand the biology of aging and the underlying mechanisms of how to potentially impede the aging process. This dataset, which will be freely accessible to the research and drug discovery communities, will provide the most complete picture of the impact of aging interventions in mice across multiple biomarkers and clinically relevant phenotypes. Leading scientists and thought leaders across the field will participate in the selection and design of the interventions. The Rejuvenome Project is expected to take approximately seven years to complete. All wet lab operations will be centered at the Buck Institute, while the dry lab computational aspects of the project will reside at the Astera Institute.

Wilson Sonsini Goodrich & Rosati advised the Buck Institute on the collaboration. The team included Alex Key and Shefali Tandon.

For more information, please see the companies’ press release.